{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:08:02Z","timestamp":1706400482903},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.thromres.2005.03.028","type":"journal-article","created":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T14:20:40Z","timestamp":1121782840000},"page":"409-416","source":"Crossref","is-referenced-by-count":5,"title":["Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency"],"prefix":"10.1016","volume":"118","author":[{"given":"Wendy","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Douketis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2005.03.028_bib1","article-title":"Cardiac and vascular disease and medication use in patients referred to a nephrologist with chronic renal insufficiency","author":"Wharton","year":"2003","journal-title":"Canadian Society of Nephrology"},{"key":"10.1016\/j.thromres.2005.03.028_bib2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1053\/ajkd.2001.29275","article-title":"Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter","volume":"38","author":"Levin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.thromres.2005.03.028_bib3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1592\/phco.20.9.771.35210","article-title":"Enoxaparin and bleeding complications in patients with and without renal insufficiency","volume":"20","author":"Gerlach","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2005.03.028_bib4","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1378\/chest.125.5.1616","article-title":"Enoxaparin use in patients with an acute coronary syndrome. Prescribing practices and bleeding risk","volume":"125","author":"Macie","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2005.03.028_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2002.120774","article-title":"Influence of patient characteristics and renal function and factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes","volume":"143","author":"Becker","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2005.03.028_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.thromres.2005.03.028_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2002-32312","article-title":"Venous thromboembolism epidemiology: implications for prevention and management","volume":"28","author":"Heit","year":"2002","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(03)12712-2","article-title":"Acute myocardial infarction","volume":"361","author":"Boersma","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2005.03.028_bib9","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/16.5.1042","article-title":"Screening for renal disease using serum creatinine: who are we missing?","volume":"16","author":"Duncan","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.thromres.2005.03.028_bib10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1681\/ASN.V781106","article-title":"Aging and the kidneys","volume":"7","author":"Epstein","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.thromres.2005.03.028_bib11","first-page":"2812","article-title":"Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration","volume":"13","author":"Clase","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.thromres.2005.03.028_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archinte.163.3.356","article-title":"Serum creatinine is an inadequate screening test for renal failure in elderly patients","volume":"163","author":"Swedko","year":"2003","journal-title":"Arch Intern Med"},{"issue":"suppl 2","key":"10.1016\/j.thromres.2005.03.028_bib13","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic renal disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.thromres.2005.03.028_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2001-17961","article-title":"How and when to monitor a patient treated with low molecular weight heparin","volume":"27","author":"Boneu","year":"2001","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1592\/phco.21.2.218.34112","article-title":"Dosing and monitoring of low-molecular-weight heparins in special populations","volume":"21","author":"Duplaga","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2005.03.028_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0002-9343(99)00129-1","article-title":"Out patient treatment of deep vein thrombosis: translating clinical trials into practice","volume":"106","author":"Dunn","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib18","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2005.03.028_bib19","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1046\/j.1538-7836.2003.00269.x","article-title":"Unresolved issues in anticoagulant therapy","volume":"1","author":"Schulman","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib20","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","article-title":"Is impaired renal function a contraindication to the use of low-molecular-weight heparin?","volume":"162","author":"Nagge","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0049-3848(91)90134-I","article-title":"Pharmacodynamics of a very low molecular weight heparin in chronic renal failure","volume":"63","author":"Hory","year":"1991","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2005.03.028_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0049-3848(91)90141-I","article-title":"Delayed elimination of enoxaparin in patients with chronic renal insufficiency","volume":"63","author":"Cadroy","year":"1991","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2005.03.028_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000186641","article-title":"Pharmacodynamics of a low molecular weight heparin (FraxiparineR) in various stages of chronic renal failure","volume":"59","author":"Goudable","year":"1991","journal-title":"Nephron"},{"key":"10.1016\/j.thromres.2005.03.028_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0037-1615034","article-title":"Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low-molecular weight heparin (nadroparin)","volume":"79","author":"Mismetti","year":"1998","journal-title":"Thrombo Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0037-1614119","article-title":"Elderly patients treated with tinzaparin (InnohepR) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days","volume":"84","author":"Siguret","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib26","doi-asserted-by":"crossref","first-page":"513S","DOI":"10.1378\/chest.126.3_suppl.513S","article-title":"Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Harrington","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2005.03.028_bib27","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.0000037106.76139.53","volume":"106","author":"Braunwald","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2005.03.028_bib28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1053\/euhj.2002.3385","article-title":"Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"23","author":"Bertrand","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2005.03.028_bib29","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","article-title":"Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Buller","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2005.03.028_bib30","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib31","first-page":"217","article-title":"Treatment of deep vein thrombosis: what factors determine appropriate treatment?","volume":"51","author":"Douketis","year":"2005","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.thromres.2005.03.028_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00063198-200109000-00019","article-title":"Outpatient treatment of patients with deep vein thrombosis and pulmonary embolism","volume":"7","author":"Wells","year":"2001","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2165\/00019053-200220140-00003","article-title":"Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome","volume":"20","author":"Brosa","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.thromres.2005.03.028_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0002-8703(00)90085-1","article-title":"Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?","volume":"139","author":"O'Brien","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2005.03.028_bib35","first-page":"931","article-title":"Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis","volume":"159","author":"Rodger","year":"1998","journal-title":"CMAJ"},{"key":"10.1016\/j.thromres.2005.03.028_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00019053-199712010-00003","article-title":"Cost-effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism","volume":"12","author":"Anderson","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.thromres.2005.03.028_bib37","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1046\/j.1538-7836.2003.00270.x","article-title":"Heparin induced thrombocytopenia","volume":"1","author":"Chong","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib38","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1016\/j.thromres.2005.03.028_bib39","first-page":"24","article-title":"Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacodynamics and metabolism in humans","volume":"26","author":"Frydman","year":"1996","journal-title":"Haemostasis"},{"issue":"Suppl 3","key":"10.1016\/j.thromres.2005.03.028_bib40","first-page":"57","article-title":"Human pharmacodynamics of low molecular weight heparins","volume":"25","author":"Cornelli","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0049-3848(91)90156-Q","article-title":"Pharmacodynamics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers","volume":"61","author":"Pedersen","year":"1991","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2005.03.028_bib42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0049-3848(00)00412-6","article-title":"Anticoagulant pharmacodynamics of tinzaparin following 175 IU\/kg subcutaneous administration to healthy volunteers","volume":"101","author":"Barrett","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2005.03.028_bib43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00002018-200225100-00005","article-title":"Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients","volume":"25","author":"Pautas","year":"2002","journal-title":"Drug Safety"},{"key":"10.1016\/j.thromres.2005.03.028_bib44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM199204093261502","article-title":"Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis","volume":"326","author":"Hull","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib45","first-page":"431","article-title":"Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis","volume":"39","author":"Barrett","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2005.03.028_bib46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1055\/s-0038-1653833","article-title":"Comparison of the pharmacokinetic profiles of three low molecular mass heparins\u2014dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)","volume":"73","author":"Collignon","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.160.2.181","article-title":"A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency","volume":"160","author":"Dolovich","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/archinte.164.12.1319","article-title":"Low-molecular-weight heparin as bridging anticoagulation in patients who require temporary interruption of warfarin for an elective surgical or invasive procedure: assessment of a standardized peri-procedural anticoagulation regimen","volume":"169","author":"Douketis","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib50","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1097\/01.ASN.0000145014.80714.35","article-title":"Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials","volume":"15","author":"Lim","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.thromres.2005.03.028_bib51","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/ajkd.2002.36331","article-title":"Pharmacodynamic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients","volume":"40","author":"Polkinghorne","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.thromres.2005.03.028_bib52","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1097\/00003246-199910000-00026","article-title":"A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration","volume":"27","author":"Reeves","year":"1999","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.thromres.2005.03.028_bib53","first-page":"97","article-title":"Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane","volume":"38","author":"Ljungberg","year":"1992","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.thromres.2005.03.028_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","article-title":"Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for the treatment of venous thromboembolic disease","volume":"134","author":"Merli","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib55","series-title":"Marketing Reports","year":"2002"},{"key":"10.1016\/j.thromres.2005.03.028_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajh.1077","article-title":"Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin","volume":"67","author":"Busby","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.thromres.2005.03.028_bib57","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/000313480006600823","article-title":"Enoxaparin associated with huge abdominal wall hematomas: a report of two cases","volume":"66","author":"Antonelli","year":"2000","journal-title":"Am Surg"},{"key":"10.1016\/j.thromres.2005.03.028_bib58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.ajkd.2003.11.012","article-title":"Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease","volume":"43","author":"Farooq","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.thromres.2005.03.028_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies","volume":"146","author":"Spinler","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2005.03.028_bib60","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org 31540) with high affinity to antithrombin III in man","volume":"74","author":"Boneau","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2005.03.028_bib61","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib62","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2005.03.028_bib63","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/01.ATV.15.4.495","article-title":"Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times","volume":"15","author":"van Amsterdam","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2005.03.028_bib64","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacologic properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2005.03.028_bib65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br J Haematol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384805002112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384805002112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T23:12:37Z","timestamp":1706397157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384805002112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0049384805002112"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2005.03.028","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}